Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Public ClinicalTrials.gov record NCT02047474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well combination chemotherapy before and after surgery works in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.
Study identification
- NCT ID
- NCT02047474
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- oxaliplatin Drug
- leucovorin calcium Drug
- irinotecan hydrochloride Drug
- fluorouracil Drug
- therapeutic conventional surgery Procedure
- laboratory biomarker analysis Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2014
- Primary completion
- Aug 15, 2022
- Completion
- Jan 13, 2024
- Last update posted
- Mar 5, 2026
2014 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 1
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Smilow Cancer Hospital at Fairfield | Fairfield | Connecticut | 06824 | — |
| Smilow Cancer Hospital at Guilford | Guilford | Connecticut | 06437 | — |
| Smilow Cancer Hospital at St. Francis Hospital | Hartford | Connecticut | 06105 | — |
| Yale University | New Haven | Connecticut | 06520-8032 | — |
| Smilow Cancer Hospital at North Haven | North Haven | Connecticut | 06473 | — |
| Smilow Cancer Hospital at Orange | Orange | Connecticut | 06477 | — |
| Smilow Cancer Hospital at Torrington | Torrington | Connecticut | 06790 | — |
| Smilow Cancer Hospital at Trumbull | Trumbull | Connecticut | 06611 | — |
| Smilow Cancer Hospital at Waterbury | Waterbury | Connecticut | 06708 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02047474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02047474 live on ClinicalTrials.gov.